Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

ABSTRACT:

Aim

To investigate the effects of off-label non-vitamin K oral anticoagulant (NOAC) dose reduction compared with on-label standard dosing in atrial fibrillation (AF) patients in routine care.

Methods

Population-based cohort study using data from the United Kingdom Clinical Practice Research Datalink, comparing adults with non-valvular AF receiving an off-label reduced NOAC dose to patients receiving an on-label standard dose. Outcomes were ischaemic stroke, major/non-major bleeding and mortality. Inverse probability of treatment weighting and inverse probability of censoring weighting on the propensity score were applied to adjust for confounding and informative censoring.

Results

Off-label dose reduction occurred in 2466 patients (8.0%), compared with 18 108 (58.5%)

SUBMITTER: van den Dries CJ 

PROVIDER: S-EPMC10091743 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature